Teva can keep generic Protonix for now
This article was originally published in The Tan Sheet
Executive SummaryA federal court decision allows Teva Pharmaceutical Industries to continue marketing the generic Rx proton pump inhibitor pantoprazole. The U.S. Court of Appeals for the Federal Circuit affirmed the denial of a motion for a preliminary injunction filed by Wyeth and Altana against the generic equivalent to Wyeth's Protonix delayed-release tablets, the Jerusalem-based firm said May 14. Pantoprazole has received a positive opinion in the European Union for a switch to nonprescription status, and has been mentioned for possible OTC switch in the U.S. (1"The Tan Sheet" Feb. 4, 2008, p. 3). Teva launched generic pantoprazole in December 2007 and said it is still involved in patent litigation with Wyeth and Altana over the product
You may also be interested in...
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with three new products including Novartis's Beovu for treating neovascular (wet) age related macular degeneration. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
The US Centers for Disease Control and Prevention is reformulating a reagent in a batch of COVID-19 tests due to inconsistent performance. See what CDC official Nancy Messonier had to say about it.